This article has been archived and may not be up to date.
Inventia Life Science Accelerates Growth with AU$35 million Series B Led by Blackbird Ventures, Launching 3D Cell Culture Platform into US Market
3 minute readPublished: Tuesday, August 16, 2022 at 1:31 pm
Company aims to democratise access to affordable biomedical research especially in cancer research and new drug development through its novel 3D cell culture platform.